Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
139 hedge funds and large institutions have $636M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 20 closing their positions.
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
3% more funds holding
Funds holding: 135 → 139 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $663M → $636M (-$26.7M)
25% less call options, than puts
Call options by funds: $539K | Put options by funds: $723K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$12.9M |
| 2 |
Millennium Management
New York
|
+$12.7M |
| 3 |
TA
Teachers Advisors
New York
|
+$8.41M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$6.66M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$7.66M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.59M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.48M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.78M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.53M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SGAM
151
Smith Group Asset Management
Dallas,
Texas
| – | -$554K | -8,278 | Closed |
|
152
Two Sigma Advisers
New York
| – | -$402K | -5,405 | Closed |
|
153
D.E. Shaw & Co
New York
| – | -$350K | -5,232 | Closed |
|
|
AI
154
Analytic Investors
Los Angeles,
California
| – | -$134K | -2,005 | Closed |
|
|
TAM
155
Tocqueville Asset Management
New York
| – | -$98K | -1,462 | Closed |
|
|
RFC
156
Russell Frank Company
Seattle,
Washington
| – | -$40K | -597 | Closed |
|
|
QT
157
Quantbot Technologies
New York
| – | -$18K | -278 | Closed |
|
|
AIM
158
Advantage Investment Management
Cedar Rapids,
Iowa
| – | -$6K | -95 | Closed |
|
|
KF
159
Krilogy Financial
St. Louis,
Missouri
| – | -$3K | -38 | Closed |
|
MACK Hedge Fund Activity: Q4 2015 in Review
139 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2015, worth a combined $636M — down 4% from $663M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MACK positions and 20 closed out — a net gain of 5 holders — while 48 added to existing stakes and 39 trimmed.
The largest buyer was Putnam Investments, adding an estimated $12.9M. The largest seller was VOYA Investment Management, cutting an estimated $7.66M.
- 139 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2015, up from 135 in Q3 2015.
- Funds reported $636M of Merrimack Pharmaceuticals, Inc. stock for Q4 2015, down 4% quarter-over-quarter.
- 25 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2015 and 20 closed out, a net change of +5 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2015 was Putnam Investments, an estimated $12.9M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2015 was VOYA Investment Management, an estimated $7.66M sold.
Based on aggregated 13F filings for Q4 2015.